person · Reporting owner
Papkoff Jacqueline Sybil
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | SVP-CSO Microbiome | December 14, 2020 | December 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date December 14, 2020 · Filed December 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,364 |
Reported balance
After 2020-12-14 transaction · row 1
1 source rowRow 1 · 2020-12-14 · Sale · Disposed 1,297 · Balance 37,364 F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2020 Filed Dec 15, 2020 21:18 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,297 | $6.15 | $7,982.78 |
DisclosureSEC source: 0001209191-20-063666 · doc4.xml · nonDerivative · entry 1 Papkoff Jacqueline Sybil · CIK 0001735729 · SVP-CSO Microbiome 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,364 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 16:16 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,254 | $14.22 | $17,830.88 |
DisclosureSEC source: 0001209191-20-021800 · doc4.xml · nonDerivative · entry 2 Papkoff Jacqueline Sybil · CIK 0001735729 · SVP-CSO Microbiome 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,661 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $14.79, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 16:16 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock (right to buy) · Derivative | 34,000 | $0.00 Strike: $14.45 | $0.00 |
DisclosureSEC source: 0001209191-20-021800 · doc4.xml · derivative · entry 3 Papkoff Jacqueline Sybil · CIK 0001735729 · SVP-CSO Microbiome 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2030-03-27 F4 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on March 29, 2021; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2024. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 16:16 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-021800 · doc4.xml · nonDerivative · entry 1 Papkoff Jacqueline Sybil · CIK 0001735729 · SVP-CSO Microbiome 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,915 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2021; March 29, 2022; March 29, 2023; and March 29, 2024. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 17:21 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,460 | $21.00 | $30,661.61 |
DisclosureSEC source: 0001209191-19-060715 · doc4.xml · nonDerivative · entry 1 Papkoff Jacqueline Sybil · CIK 0001735729 · SVP-CSO Microbiome 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,915 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.02, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| October 01, 2019 Filed Oct 1, 2019 18:10 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Options (right to buy) · Derivative | 27,500 | $0.00 Strike: $9.31 | $0.00 |
DisclosureSEC source: 0001209191-19-051359 · doc4.xml · derivative · entry 1 Papkoff Jacqueline Sybil · CIK 0001735729 · SVP-CSO Microbiome 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2029-10-01 F1 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, October 1, 2020; and the remaining 75% shall vest in 36 approximately equal monthly installments, with the options becoming fully vested on October 1, 2023. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 16:38 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 27,500 | $0.00 Strike: $19.69 | $0.00 |
DisclosureSEC source: 0001144204-19-017753 · tv517880_4.xml · derivative · entry 2 Papkoff Jacqueline Sybil · CIK 0001735729 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2029-03-29 F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, March 29, 2020; and the remaining 75% shall vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2023. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 16:38 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-017753 · tv517880_4.xml · nonDerivative · entry 1 Papkoff Jacqueline Sybil · CIK 0001735729 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,375 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2020; March 29, 2021; March 29, 2022; and March 29, 2023. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 16:31 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 21,250 | $0.00 Strike: $24.19 | $0.00 |
DisclosureSEC source: 0001144204-18-064671 · tv509185_form4.xml · derivative · entry 2 Papkoff Jacqueline Sybil · CIK 0001735729 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 21,250 shares Expires 2028-12-12 F2 · derivative.exercise_date: Grant of stock options under the 2018 Plan. The stock options vest in approximately equal annual installments, assuming continuous service on each vesting date, on the first, second and third anniversaries of the date of grant. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 16:31 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-064671 · tv509185_form4.xml · nonDerivative · entry 1 Papkoff Jacqueline Sybil · CIK 0001735729 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 F1 · shares: Represents shares of common stock issuable under a time-based restricted stock unit (RSU) award dated December 12, 2018 that was granted under Assembly Biosciences, Inc.'s 2018 Stock Incentive Plan (2018 Plan). The RSUs vest in approximately equal annual installments, assuming continuous service on each vesting date, on the first, second and third anniversaries of the date of grant. Read SEC document |
| April 02, 2018 Filed Apr 2, 2018 18:11 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 106,200 | $0.00 Strike: $46.75 | $0.00 |
DisclosureSEC source: 0001144204-18-018750 · tv490173_form4.xml · derivative · entry 1 Papkoff Jacqueline Sybil · CIK 0001735729 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,200 Underlying: Common Stock · 106,200 shares Expires 2028-04-02 F1 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, April 2, 2019; and the remaining 75% shall vest in 36 equal monthly installments, with the options becoming fully vested on April 2, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.